Owlstone Medical
SQI Diagnostics, Owlstone Medical Ink MOU for Lung Infection, Transplant Rejection
The companies intend to work together on breath-based biomarkers for Aspergillus lung infection and lung transplant rejection.
Owlstone Medical Raises $58M in Series D Financing Round
The company said it has a pipeline of research-use-only panels and diagnostic tests that are in development for lung cancer, liver disease, and respiratory disease.
Long-Haul COVID-19 Respiratory Infections, Pneumonia Targeted by Breath-Based Tests From Avisa Dx
Premium
Avisa is preparing an Investigational Device Exemption application to the FDA to facilitate a pivotal study for its portable, point-of-care drug-device breath tests.
Owlstone Medical Entering Digestive Health Dx Space With Launch of Breath-Based Testing Service
Premium
The company is preparing to provide a clinical testing service that integrates hydrogen and methane biomarkers for digestive health conditions.
Owlstone Medical Partners With UK Clinics to Develop Breath Tests for Digestive Health
Owlstone Medical said the collaboration aims to enable the efficient scaling of hydrogen/methane breath testing for gut health.
Sep 19, 2019
Mar 21, 2019
Feb 20, 2019
Nov 7, 2018